(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 57.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.66%.
Cormedix's revenue in 2025 is $82,553,827.On average, 2 Wall Street analysts forecast CRMD's revenue for 2025 to be $8,978,628,358, with the lowest CRMD revenue forecast at $8,491,647,307, and the highest CRMD revenue forecast at $9,465,609,410. On average, 2 Wall Street analysts forecast CRMD's revenue for 2026 to be $14,849,869,965, with the lowest CRMD revenue forecast at $12,811,399,839, and the highest CRMD revenue forecast at $16,888,340,091.
In 2027, CRMD is forecast to generate $22,056,579,107 in revenue, with the lowest revenue forecast at $22,056,579,107 and the highest revenue forecast at $22,056,579,107.